Prof Janine Kirby
@j9kirby.bsky.social
Researcher & Lecturer based in SITraN, University of Sheffield. Tweeting on MND/ALS, Neuroscience, Advanced Therapies and Education
Reposted by Prof Janine Kirby
We’ve just published a report to tell you all about what we’ve been up to in the second year of our research strategy ‘Catalysing a Cure’ - here are the highlights 🔬
For more details and to read the report in full, click below 👇
www.myname5doddie.co.uk/whats-on/art...
For more details and to read the report in full, click below 👇
www.myname5doddie.co.uk/whats-on/art...
December 17, 2025 at 9:26 AM
We’ve just published a report to tell you all about what we’ve been up to in the second year of our research strategy ‘Catalysing a Cure’ - here are the highlights 🔬
For more details and to read the report in full, click below 👇
www.myname5doddie.co.uk/whats-on/art...
For more details and to read the report in full, click below 👇
www.myname5doddie.co.uk/whats-on/art...
Reposted by Prof Janine Kirby
Doddie said “love, fun & hope” should be one of our key pillars. That still guides us today💗💙💛
At our Discovery Network Showcase, researchers, people living with and affected by MND, and industry partners shared what inspires them (love), makes them smile (fun) & gives them hope in MND research
At our Discovery Network Showcase, researchers, people living with and affected by MND, and industry partners shared what inspires them (love), makes them smile (fun) & gives them hope in MND research
December 11, 2025 at 3:43 PM
Doddie said “love, fun & hope” should be one of our key pillars. That still guides us today💗💙💛
At our Discovery Network Showcase, researchers, people living with and affected by MND, and industry partners shared what inspires them (love), makes them smile (fun) & gives them hope in MND research
At our Discovery Network Showcase, researchers, people living with and affected by MND, and industry partners shared what inspires them (love), makes them smile (fun) & gives them hope in MND research
Reposted by Prof Janine Kirby
Sign up for Doddie Aid 2026 now‼️ doddieaid.com
December 2, 2025 at 12:11 PM
Sign up for Doddie Aid 2026 now‼️ doddieaid.com
Reposted by Prof Janine Kirby
We have invested almost £3m to help MND clinical trial centres recruit the staff they need.
When Doddie was diagnosed, he was frustrated at the lack of clinical trials in the UK. Today’s landscape is significantly different and we’re proud to support that 👇
www.myname5doddie.co.uk/whats-on/art...
When Doddie was diagnosed, he was frustrated at the lack of clinical trials in the UK. Today’s landscape is significantly different and we’re proud to support that 👇
www.myname5doddie.co.uk/whats-on/art...
November 18, 2025 at 4:06 PM
We have invested almost £3m to help MND clinical trial centres recruit the staff they need.
When Doddie was diagnosed, he was frustrated at the lack of clinical trials in the UK. Today’s landscape is significantly different and we’re proud to support that 👇
www.myname5doddie.co.uk/whats-on/art...
When Doddie was diagnosed, he was frustrated at the lack of clinical trials in the UK. Today’s landscape is significantly different and we’re proud to support that 👇
www.myname5doddie.co.uk/whats-on/art...
Reposted by Prof Janine Kirby
We’ve spent £2 million on nine new MND research projects through our Advancing Treatments and Catalyst Awards, which all aim to accelerate the search for effective treatments 🔬
Find out more about the projects here 👇
www.myname5doddie.co.uk/whats-on/art...
Find out more about the projects here 👇
www.myname5doddie.co.uk/whats-on/art...
November 5, 2025 at 12:59 PM
We’ve spent £2 million on nine new MND research projects through our Advancing Treatments and Catalyst Awards, which all aim to accelerate the search for effective treatments 🔬
Find out more about the projects here 👇
www.myname5doddie.co.uk/whats-on/art...
Find out more about the projects here 👇
www.myname5doddie.co.uk/whats-on/art...
Reposted by Prof Janine Kirby
This is a landmark paper showing a predictive test for #ALS #MND up to 40 years before onset and able to predict age of onset. Huge implications
www.nature.com/articles/s41...
www.nature.com/articles/s41...
A plasma proteomics-based candidate biomarker panel predictive of amyotrophic lateral sclerosis - Nature Medicine
Plasma proteomic analysis of presymptomatic individuals with amyotrophic lateral sclerosis identifies novel disease-associated proteins and enables the development of an accurate diagnostic biomarker ...
www.nature.com
August 29, 2025 at 8:05 AM
This is a landmark paper showing a predictive test for #ALS #MND up to 40 years before onset and able to predict age of onset. Huge implications
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Great couple of days attending the School of Medicine and Population Health graduations of PGR and MBChB students @sheffielduni.bsky.social
July 25, 2025 at 6:38 PM
Great couple of days attending the School of Medicine and Population Health graduations of PGR and MBChB students @sheffielduni.bsky.social
@lifearc.bsky.social are now on Bluesky
Hello Bluesky 👋🦋
We're a medical research not-for-profit helping to turn scientific discoveries into treatments and diagnostics. We convene experts, conduct science, give advice and fund rare disease research and global health challenges.
Find out more ⤵️
www.lifearc.org/about-us/
We're a medical research not-for-profit helping to turn scientific discoveries into treatments and diagnostics. We convene experts, conduct science, give advice and fund rare disease research and global health challenges.
Find out more ⤵️
www.lifearc.org/about-us/
www.lifearc.org
July 19, 2025 at 10:58 AM
@lifearc.bsky.social are now on Bluesky
Reposted by Prof Janine Kirby
We’re proud to feature in the AMRC's new report on translating research for our jointly funded work with Motor Neurone Disease Association and LifeArc 🤝
@amrc-uk.bsky.social @mndassoc.bsky.social @lifearc.bsky.social
You can view the full report here 👇
bit.ly/4lTL049
@amrc-uk.bsky.social @mndassoc.bsky.social @lifearc.bsky.social
You can view the full report here 👇
bit.ly/4lTL049
July 17, 2025 at 4:05 PM
We’re proud to feature in the AMRC's new report on translating research for our jointly funded work with Motor Neurone Disease Association and LifeArc 🤝
@amrc-uk.bsky.social @mndassoc.bsky.social @lifearc.bsky.social
You can view the full report here 👇
bit.ly/4lTL049
@amrc-uk.bsky.social @mndassoc.bsky.social @lifearc.bsky.social
You can view the full report here 👇
bit.ly/4lTL049
Great to see this work come to fruition and highlighted by @sheffielduni.bsky.social
We may be closer to treating motor neuron disease (or #ALS) thanks to a new clinical trial involving Sheffield University scientists.
We've a primer 🧵 from the MIROCALS trial, published in @thelancet.bsky.social, below, or jump to the story on our website 👇 1/5
www.sheffield.ac.uk/news/landmar...
We've a primer 🧵 from the MIROCALS trial, published in @thelancet.bsky.social, below, or jump to the story on our website 👇 1/5
www.sheffield.ac.uk/news/landmar...
Landmark MIROCALS clinical trial provides new insight into treatment of MND
Results of the landmark MIROCALS clinical trial, involving researchers from the University of Sheffield, have revealed new insights into the treatment of motor neuron disease (MND).
www.sheffield.ac.uk
May 10, 2025 at 8:43 AM
Great to see this work come to fruition and highlighted by @sheffielduni.bsky.social
Reposted by Prof Janine Kirby
Our paper describing the results of the MIROCALS trial of low-dose interleukin-2 in #ALS #MND is out in the Lancet @thelancet.bsky.social
Open access
Read it here:
www.thelancet.com/journals/lan...
Open access
Read it here:
www.thelancet.com/journals/lan...
Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial
With this treatment schedule, IL-2LD resulted in a non-significant reduction in mortality
in the primary unadjusted analysis. However, the difference between the results of
unadjusted and adjusted ana...
www.thelancet.com
May 9, 2025 at 11:07 PM
Our paper describing the results of the MIROCALS trial of low-dose interleukin-2 in #ALS #MND is out in the Lancet @thelancet.bsky.social
Open access
Read it here:
www.thelancet.com/journals/lan...
Open access
Read it here:
www.thelancet.com/journals/lan...
Reposted by Prof Janine Kirby
Introducing our new Research snapshot series. Where we highlight the latest #MND studies reported by Readable Research @sheffielduni.bsky.social 🔬
First up: a look at toxic proteins in a mouse model of C9orf72-related MND and what it tells us about future treatments.
ukmndri.org/2025/04/14/r...
First up: a look at toxic proteins in a mouse model of C9orf72-related MND and what it tells us about future treatments.
ukmndri.org/2025/04/14/r...
Understanding the production of toxic proteins in MND
A new study has explored how toxic proteins build up in the nervous system and whether future treatments might help stop them.
ukmndri.org
April 14, 2025 at 10:46 AM
Introducing our new Research snapshot series. Where we highlight the latest #MND studies reported by Readable Research @sheffielduni.bsky.social 🔬
First up: a look at toxic proteins in a mouse model of C9orf72-related MND and what it tells us about future treatments.
ukmndri.org/2025/04/14/r...
First up: a look at toxic proteins in a mouse model of C9orf72-related MND and what it tells us about future treatments.
ukmndri.org/2025/04/14/r...
Reposted by Prof Janine Kirby
Did you catch Hamish, Kenny Logan & our Director of Research, Dr Madina Kara, on BBC Breakfast this morning?📺
Kenny unveiled the plans for his Doddie’s Lions Challenge, a 555-mile cycle round Ireland, with the aim to raise over £500,000 for the Foundation & Irish Motor Neurone Disease Association
Kenny unveiled the plans for his Doddie’s Lions Challenge, a 555-mile cycle round Ireland, with the aim to raise over £500,000 for the Foundation & Irish Motor Neurone Disease Association
April 14, 2025 at 4:14 PM
Did you catch Hamish, Kenny Logan & our Director of Research, Dr Madina Kara, on BBC Breakfast this morning?📺
Kenny unveiled the plans for his Doddie’s Lions Challenge, a 555-mile cycle round Ireland, with the aim to raise over £500,000 for the Foundation & Irish Motor Neurone Disease Association
Kenny unveiled the plans for his Doddie’s Lions Challenge, a 555-mile cycle round Ireland, with the aim to raise over £500,000 for the Foundation & Irish Motor Neurone Disease Association
Reposted by Prof Janine Kirby
Check out our new review of C9orf72 ALS in @thelancetneuro.bsky.social with Sarah Mizielinska, Rosa Rademakers and others! Was fun to co-write but tough to collate such incredible progress into a one article: authors.elsevier.com/c/1ke765FFzL...
February 21, 2025 at 9:56 AM
Check out our new review of C9orf72 ALS in @thelancetneuro.bsky.social with Sarah Mizielinska, Rosa Rademakers and others! Was fun to co-write but tough to collate such incredible progress into a one article: authors.elsevier.com/c/1ke765FFzL...
SMA treated in the womb
www.nature.com/articles/d41...
www.nature.com/articles/d41...
Rare genetic disorder treated in womb for the first time
The child, who is now almost three years old, shows no signs of the often fatal motor neuron disease.
www.nature.com
February 20, 2025 at 9:58 PM
SMA treated in the womb
www.nature.com/articles/d41...
www.nature.com/articles/d41...
Reposted by Prof Janine Kirby
Welcome to Brian Dickie @bd365.bsky.social on BlueSky! Please give him a follow if you work on neurodegeneration, especially ALS/MND!
February 19, 2025 at 9:00 AM
Welcome to Brian Dickie @bd365.bsky.social on BlueSky! Please give him a follow if you work on neurodegeneration, especially ALS/MND!
Reposted by Prof Janine Kirby
Many people with #MND are asking about ellorarxine.
How are new drugs approved, and what does the evidence say about this research and drug? 🔬
We break down the drug development process and how we’re working to speed it up.
ukmndri.org/2025/02/07/a...
How are new drugs approved, and what does the evidence say about this research and drug? 🔬
We break down the drug development process and how we’re working to speed it up.
ukmndri.org/2025/02/07/a...
An update on Ellorarxine - UKMNDRI
As neurologists specialising in the care of people living with motor neuron disease, we are receiving increasing enquiries about a drug called ellorarxine. Many of our patients are asking for access, ...
ukmndri.org
February 7, 2025 at 9:50 AM
Many people with #MND are asking about ellorarxine.
How are new drugs approved, and what does the evidence say about this research and drug? 🔬
We break down the drug development process and how we’re working to speed it up.
ukmndri.org/2025/02/07/a...
How are new drugs approved, and what does the evidence say about this research and drug? 🔬
We break down the drug development process and how we’re working to speed it up.
ukmndri.org/2025/02/07/a...
Reposted by Prof Janine Kirby
Perspective, led by Martin, on the current application and future potential for blood neurofilament light chain level in neurological disorders, including #ALS pubmed.ncbi.nlm.nih.gov/39845125/
Blood level of neurofilament light chain as a biomarker for neurological disorders - PubMed
Blood level of neurofilament light chain as a biomarker for neurological disorders
pubmed.ncbi.nlm.nih.gov
January 29, 2025 at 10:14 AM
Perspective, led by Martin, on the current application and future potential for blood neurofilament light chain level in neurological disorders, including #ALS pubmed.ncbi.nlm.nih.gov/39845125/
Reposted by Prof Janine Kirby
🚨We're working to accelerate the development of new treatments for #ALS.
Read more about how our pioneering study, EXPERTS-ALS, aims to rapidly screen potential drugs for evidence that they can slow progression in people with ALS.
🔗 Find out more 👇 ukmndri.org/2025/01/29/s...
Read more about how our pioneering study, EXPERTS-ALS, aims to rapidly screen potential drugs for evidence that they can slow progression in people with ALS.
🔗 Find out more 👇 ukmndri.org/2025/01/29/s...
Showcasing our groundbreaking EXPERTS-ALS study for MND treatments - UKMNDRI
EXPERTS-ALS is a ground-breaking initiative to accelerate the development of new treatments for amyotrophic lateral sclerosis (ALS).
We’re excited to showcase one of our flagship projects, the EXPErim...
ukmndri.org
January 29, 2025 at 10:17 AM
🚨We're working to accelerate the development of new treatments for #ALS.
Read more about how our pioneering study, EXPERTS-ALS, aims to rapidly screen potential drugs for evidence that they can slow progression in people with ALS.
🔗 Find out more 👇 ukmndri.org/2025/01/29/s...
Read more about how our pioneering study, EXPERTS-ALS, aims to rapidly screen potential drugs for evidence that they can slow progression in people with ALS.
🔗 Find out more 👇 ukmndri.org/2025/01/29/s...
Reposted by Prof Janine Kirby
Take a look at the 'Countdown to a Cure' report which demonstrates some of the exciting and promising translational UK research being funded by the MND Association.
www.mndassociation.org/research/cou...
www.mndassociation.org/research/cou...
Countdown to a cure
Get access to 'Countdown to a cure' which provides an overview of the innovative research the MND Association is funding, the increased collaboration across MND research, and a look at new and improve...
www.mndassociation.org
January 15, 2025 at 10:50 AM
Take a look at the 'Countdown to a Cure' report which demonstrates some of the exciting and promising translational UK research being funded by the MND Association.
www.mndassociation.org/research/cou...
www.mndassociation.org/research/cou...
Reposted by Prof Janine Kirby
New paper to reflect on the main challenges in phase 2 #ALS #MND trials. Key issues relate too short study durations, reliance on the wrong outcome measures, absence of biomarkers, statistical issues, over-interpretation of 'clinical trends' and miscommunication. academic.oup.com/brain/articl...
Rethinking phase 2 trials in amyotrophic lateral sclerosis
There is a long history of ALS therapies being promoted on the basis of Phase 2 data, which then fail to translate into meaningful benefits in Phase 3 tria
academic.oup.com
December 10, 2024 at 3:14 PM
New paper to reflect on the main challenges in phase 2 #ALS #MND trials. Key issues relate too short study durations, reliance on the wrong outcome measures, absence of biomarkers, statistical issues, over-interpretation of 'clinical trends' and miscommunication. academic.oup.com/brain/articl...
Reposted by Prof Janine Kirby
Poster session B, 5.30-7 7th December
For anyone heading to #alsmndsymp in montreal look out for @mndassoc.bsky.social funded student Charlotte Gale-Rogers work on C9orf72 DPR disruption to locomotor rhythmicity using some of our fly models. Poster IVV-26.
December 7, 2024 at 6:31 PM
Poster session B, 5.30-7 7th December
Reposted by Prof Janine Kirby
We are delighted to announce that Dr Alfredo Iacoangeli was awarded the esteemed Paulo Gontijo Award at the opening of the Montreal 32nd International #ALS/#MND Symposium. This global accolade celebrates excellence in MND research.
Read more here: ukmndri.org/2024/12/07/u...
Read more here: ukmndri.org/2024/12/07/u...
UK researcher wins prestigious Paulo Gontijo Award for MND Research - UKMNDRI
Dr. Alfredo Iacoangeli has been awarded the prestigious Paulo Gontijo Award, recognising his vital contributions to MND research.
We are delighted to announce that Dr Alfredo Iacoangeli was awarded t...
ukmndri.org
December 7, 2024 at 9:32 PM
We are delighted to announce that Dr Alfredo Iacoangeli was awarded the esteemed Paulo Gontijo Award at the opening of the Montreal 32nd International #ALS/#MND Symposium. This global accolade celebrates excellence in MND research.
Read more here: ukmndri.org/2024/12/07/u...
Read more here: ukmndri.org/2024/12/07/u...
Reposted by Prof Janine Kirby
November 18, 2024 at 12:07 PM